Ariceum Therapeutics is developing novel drugs for systemic targeted radiotherapy (STR)
Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Our lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2...
Ariceum Therapeutics is developing novel drugs for systemic targeted radiotherapy (STR)
Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Our lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.